Why the MGC Pharma (ASX:MXC) share price is zooming 13% higher today

The MGC Pharma (ASX: MXC) share price is up 13% in morning trade. We look at the latest from the ASX cannabis share.

| More on:
cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is off to the races today, up 13% at the time of writing.

The bio-pharma company produces and develops cannabis-derived medicines.

Let's take a look at the ASX cannabis share's latest product orders and revenue stream.

What did MGC Pharma report today?

The MGC Pharma share price is rocketing higher after the company reported it had completed the delivery of its first bulk order of ArtemiC Rescue in March to Swiss PharmaCan AG. The bulk order of its medicinal food supplement delivered approximately $425,000 in wholesale production revenue.

Swiss PharmaCan's purchase helped drive MGC Pharma to record quarterly sales revenue from its "proprietary phytomedicine product line". The ASX cannabis share reported it had generated roughly $880,000 of revenue during the March 2021 quarter.

The company also said March brought in its best single month's sales revenue so far from its pharmaceutical-grade phytomedicine products, driven by sales of its MP product line in Australia.

Words from the management

Commenting on the results, MGC Pharma global chief sales officer Nicole Godresse said:

In recent months we have seen rapid sales growth of our medical cannabis products as a direct result of our strategy to broaden our core prescriber base, diversify and expand our revenue streams and build additional strategic alliances. It is pleasing to see these strategies starting to translate into positive commercial outcomes and we expect this strong growth momentum to continue in 2021 and beyond.

MGC Pharma managing director Roby Zomer added:

We are very pleased to complete our first batch purchase order for ArtemiC Rescue under our Swiss PharmaCan agreement. This, combined with sales growth of other pharma grade cannabinoid products in key markets, has helped to deliver the strongest month and quarter of revenue growth for the company to date.

MGC Pharma's detailed March quarterly activity report is expected within the next few weeks.

MGC Pharma share price snapshot

Over the past 12 months, the MGC Pharma share price has gained 130%, handily outpacing the 35% gains posted by the All Ordinaries Index (ASX: XAO) over that same period.

With today's intraday gains factored in, the MGC Pharma share price is up 245% year-to-date.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

a pot of gold at the end of a rainbow
Dividend Investing

2 ASX shares I'm planning to own until I'm 100

These businesses have ultra-long-term prospects.

Read more »

A male electricity worker in hard hat and high visibility vest stands underneath large electricity generation towers as he holds a laptop computer and gazes up at the high voltage wires overhead.
Share Market News

Origin Energy to keep Eraring Power Station running until 2029

Origin Energy extends Eraring Power Station operations to 2029, backing grid stability and supporting NSW’s energy transition.

Read more »

An excited man stretches his arms out above his head as he reaches a mountain peak.
Share Market News

BHP lifts copper guidance after record half-year output

BHP lifts copper production guidance after setting new operational records in copper and iron ore for the half year ended…

Read more »

Man putting in a coin in a coin jar with piles of coins next to it.
Broker Notes

Two ASX penny stocks Bell Potter thinks are worth watching in 2026

Bell Potter is tipping upside on these penny stocks.

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Share Market News

HUB24 posts record inflows in Q2 FY26 earnings

HUB24 posts record Q2 FY26 inflows, growing funds and expanding its retirement and technology offerings.

Read more »

CEO of a company talking.
Share Market News

AMP appoints Blair Vernon as CEO, Alexis George to retire

AMP has appointed Blair Vernon as CEO, with Alexis George set to retire after five years of transformation and growth.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Share Market News

Telix Pharmaceuticals receives China's nod for Illuccix prostate cancer imaging NDA

The Chinese regulator has accepted the New Drug Application for Illuccix, Telix’s lead imaging agent for prostate cancer.

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Technology Shares

2 ASX 200 shares that could be top buys for growth

The ASX's biggest growth names still have a lot of potential.

Read more »